Al­ny­lam, Roche’s RNAi can­di­date scores mid-stage win in hy­per­ten­sion

Al­ny­lam’s zilebe­sir­an met the pri­ma­ry end­point and cer­tain sec­ondary end­points in a Phase II dose-rang­ing tri­al in a read­out that ar­rived less than six weeks af­ter Roche an­nounced it would pay $310 mil­lion to co-de­vel­op and co-com­mer­cial­ize the ther­a­py.

Al­ny­lam re­vealed topline da­ta Thurs­day from the KAR­DIA-1 tri­al, which en­rolled 394 pa­tients across five arms and test­ed zilebe­sir­an as a monother­a­py in adults with mild to mod­er­ate hy­per­ten­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER